Glucose Dependent Insulinotropic Receptor Industry Research Report 2025
Description
Summary
According to APO Research, The global Glucose Dependent Insulinotropic Receptor market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Glucose Dependent Insulinotropic Receptor include Takeda Pharmaceutical Co Ltd, Novartis AG, Merck & Co Inc, GlaxoSmithKline Plc, Amgen Inc, Yuhan Corp, Taisho Pharmaceutical Holdings Co Ltd, Kowa Co Ltd and Hyundai Pharmaceutical Co Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glucose Dependent Insulinotropic Receptor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucose Dependent Insulinotropic Receptor.
The Glucose Dependent Insulinotropic Receptor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Glucose Dependent Insulinotropic Receptor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Glucose Dependent Insulinotropic Receptor Segment by Company
Takeda Pharmaceutical Co Ltd
Novartis AG
Merck & Co Inc
GlaxoSmithKline Plc
Amgen Inc
Yuhan Corp
Taisho Pharmaceutical Holdings Co Ltd
Kowa Co Ltd
Hyundai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Dong-A Socio Holdings Co Ltd
CymaBay Therapeutics Inc
Arena Pharmaceuticals Inc
Glucose Dependent Insulinotropic Receptor Segment by Type
MBX-2982
HOB-047
HD-0471953
HD-0471042
GSK-2041706
DA-1241
Others
Glucose Dependent Insulinotropic Receptor Segment by Application
Type 2 Diabetes
Obesity
Chronic Obstructive Pulmonary Disease (COPD)
Dyslipidemia
Others
Glucose Dependent Insulinotropic Receptor Segment by Application
Type 2 Diabetes
Obesity
Chronic Obstructive Pulmonary Disease (COPD)
Dyslipidemia
Others
Glucose Dependent Insulinotropic Receptor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucose Dependent Insulinotropic Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucose Dependent Insulinotropic Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucose Dependent Insulinotropic Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Glucose Dependent Insulinotropic Receptor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Glucose Dependent Insulinotropic Receptor market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Glucose Dependent Insulinotropic Receptor include Takeda Pharmaceutical Co Ltd, Novartis AG, Merck & Co Inc, GlaxoSmithKline Plc, Amgen Inc, Yuhan Corp, Taisho Pharmaceutical Holdings Co Ltd, Kowa Co Ltd and Hyundai Pharmaceutical Co Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glucose Dependent Insulinotropic Receptor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucose Dependent Insulinotropic Receptor.
The Glucose Dependent Insulinotropic Receptor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Glucose Dependent Insulinotropic Receptor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Glucose Dependent Insulinotropic Receptor Segment by Company
Takeda Pharmaceutical Co Ltd
Novartis AG
Merck & Co Inc
GlaxoSmithKline Plc
Amgen Inc
Yuhan Corp
Taisho Pharmaceutical Holdings Co Ltd
Kowa Co Ltd
Hyundai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Dong-A Socio Holdings Co Ltd
CymaBay Therapeutics Inc
Arena Pharmaceuticals Inc
Glucose Dependent Insulinotropic Receptor Segment by Type
MBX-2982
HOB-047
HD-0471953
HD-0471042
GSK-2041706
DA-1241
Others
Glucose Dependent Insulinotropic Receptor Segment by Application
Type 2 Diabetes
Obesity
Chronic Obstructive Pulmonary Disease (COPD)
Dyslipidemia
Others
Glucose Dependent Insulinotropic Receptor Segment by Application
Type 2 Diabetes
Obesity
Chronic Obstructive Pulmonary Disease (COPD)
Dyslipidemia
Others
Glucose Dependent Insulinotropic Receptor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucose Dependent Insulinotropic Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucose Dependent Insulinotropic Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucose Dependent Insulinotropic Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Glucose Dependent Insulinotropic Receptor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
120 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Glucose Dependent Insulinotropic Receptor by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 MBX-2982
- 2.2.3 HOB-047
- 2.2.4 HD-0471953
- 2.2.5 HD-0471042
- 2.2.6 GSK-2041706
- 2.2.7 DA-1241
- 2.2.8 Others
- 2.3 Glucose Dependent Insulinotropic Receptor by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Type 2 Diabetes
- 2.3.3 Obesity
- 2.3.4 Chronic Obstructive Pulmonary Disease (COPD)
- 2.3.5 Dyslipidemia
- 2.3.6 Others
- 2.4 Assumptions and Limitations
- 3 Glucose Dependent Insulinotropic Receptor Breakdown Data by Type
- 3.1 Global Glucose Dependent Insulinotropic Receptor Historic Market Size by Type (2020-2025)
- 3.2 Global Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Type (2026-2031)
- 4 Glucose Dependent Insulinotropic Receptor Breakdown Data by Application
- 4.1 Global Glucose Dependent Insulinotropic Receptor Historic Market Size by Application (2020-2025)
- 4.2 Global Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Glucose Dependent Insulinotropic Receptor Market Perspective (2020-2031)
- 5.2 Global Glucose Dependent Insulinotropic Receptor Growth Trends by Region
- 5.2.1 Global Glucose Dependent Insulinotropic Receptor Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Glucose Dependent Insulinotropic Receptor Historic Market Size by Region (2020-2025)
- 5.2.3 Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Region (2026-2031)
- 5.3 Glucose Dependent Insulinotropic Receptor Market Dynamics
- 5.3.1 Glucose Dependent Insulinotropic Receptor Industry Trends
- 5.3.2 Glucose Dependent Insulinotropic Receptor Market Drivers
- 5.3.3 Glucose Dependent Insulinotropic Receptor Market Challenges
- 5.3.4 Glucose Dependent Insulinotropic Receptor Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Glucose Dependent Insulinotropic Receptor Players by Revenue
- 6.1.1 Global Top Glucose Dependent Insulinotropic Receptor Players by Revenue (2020-2025)
- 6.1.2 Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Players (2020-2025)
- 6.2 Global Glucose Dependent Insulinotropic Receptor Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Glucose Dependent Insulinotropic Receptor Head Office and Area Served
- 6.4 Global Glucose Dependent Insulinotropic Receptor Players, Product Type & Application
- 6.5 Global Glucose Dependent Insulinotropic Receptor Manufacturers Established Date
- 6.6 Global Glucose Dependent Insulinotropic Receptor Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Glucose Dependent Insulinotropic Receptor Market Size (2020-2031)
- 7.2 North America Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025)
- 7.4 North America Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Glucose Dependent Insulinotropic Receptor Market Size (2020-2031)
- 8.2 Europe Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025)
- 8.4 Europe Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Size (2020-2031)
- 9.2 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Glucose Dependent Insulinotropic Receptor Market Size (2020-2031)
- 10.2 South America Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025)
- 10.4 South America Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size (2020-2031)
- 11.2 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Takeda Pharmaceutical Co Ltd
- 12.1.1 Takeda Pharmaceutical Co Ltd Company Information
- 12.1.2 Takeda Pharmaceutical Co Ltd Business Overview
- 12.1.3 Takeda Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.1.4 Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.2.4 Novartis AG Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Merck & Co Inc
- 12.3.1 Merck & Co Inc Company Information
- 12.3.2 Merck & Co Inc Business Overview
- 12.3.3 Merck & Co Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.3.4 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.3.5 Merck & Co Inc Recent Developments
- 12.4 GlaxoSmithKline Plc
- 12.4.1 GlaxoSmithKline Plc Company Information
- 12.4.2 GlaxoSmithKline Plc Business Overview
- 12.4.3 GlaxoSmithKline Plc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.4.4 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.4.5 GlaxoSmithKline Plc Recent Developments
- 12.5 Amgen Inc
- 12.5.1 Amgen Inc Company Information
- 12.5.2 Amgen Inc Business Overview
- 12.5.3 Amgen Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.5.4 Amgen Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.5.5 Amgen Inc Recent Developments
- 12.6 Yuhan Corp
- 12.6.1 Yuhan Corp Company Information
- 12.6.2 Yuhan Corp Business Overview
- 12.6.3 Yuhan Corp Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.6.4 Yuhan Corp Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.6.5 Yuhan Corp Recent Developments
- 12.7 Taisho Pharmaceutical Holdings Co Ltd
- 12.7.1 Taisho Pharmaceutical Holdings Co Ltd Company Information
- 12.7.2 Taisho Pharmaceutical Holdings Co Ltd Business Overview
- 12.7.3 Taisho Pharmaceutical Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.7.4 Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.7.5 Taisho Pharmaceutical Holdings Co Ltd Recent Developments
- 12.8 Kowa Co Ltd
- 12.8.1 Kowa Co Ltd Company Information
- 12.8.2 Kowa Co Ltd Business Overview
- 12.8.3 Kowa Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.8.4 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.8.5 Kowa Co Ltd Recent Developments
- 12.9 Hyundai Pharmaceutical Co Ltd
- 12.9.1 Hyundai Pharmaceutical Co Ltd Company Information
- 12.9.2 Hyundai Pharmaceutical Co Ltd Business Overview
- 12.9.3 Hyundai Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.9.4 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.9.5 Hyundai Pharmaceutical Co Ltd Recent Developments
- 12.10 F. Hoffmann-La Roche Ltd
- 12.10.1 F. Hoffmann-La Roche Ltd Company Information
- 12.10.2 F. Hoffmann-La Roche Ltd Business Overview
- 12.10.3 F. Hoffmann-La Roche Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.10.4 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.10.5 F. Hoffmann-La Roche Ltd Recent Developments
- 12.11 Dong-A Socio Holdings Co Ltd
- 12.11.1 Dong-A Socio Holdings Co Ltd Company Information
- 12.11.2 Dong-A Socio Holdings Co Ltd Business Overview
- 12.11.3 Dong-A Socio Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.11.4 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.11.5 Dong-A Socio Holdings Co Ltd Recent Developments
- 12.12 CymaBay Therapeutics Inc
- 12.12.1 CymaBay Therapeutics Inc Company Information
- 12.12.2 CymaBay Therapeutics Inc Business Overview
- 12.12.3 CymaBay Therapeutics Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.12.4 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.12.5 CymaBay Therapeutics Inc Recent Developments
- 12.13 Arena Pharmaceuticals Inc
- 12.13.1 Arena Pharmaceuticals Inc Company Information
- 12.13.2 Arena Pharmaceuticals Inc Business Overview
- 12.13.3 Arena Pharmaceuticals Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- 12.13.4 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.13.5 Arena Pharmaceuticals Inc Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Glucose Dependent Insulinotropic Receptor Market Size by Type (2020-2025) & (US$ Million)
- Table 6. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Type (2020-2025)
- Table 7. Global Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Type (2026-2031) & (US$ Million)
- Table 8. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Type (2026-2031)
- Table 9. Global Glucose Dependent Insulinotropic Receptor Market Size by Application (2020-2025) & (US$ Million)
- Table 10. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Application (2020-2025)
- Table 11. Global Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Application (2026-2031) & (US$ Million)
- Table 12. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Application (2026-2031)
- Table 13. Global Glucose Dependent Insulinotropic Receptor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 14. Global Glucose Dependent Insulinotropic Receptor Market Size by Region (2020-2025) & (US$ Million)
- Table 15. Global Glucose Dependent Insulinotropic Receptor Market Share by Region (2020-2025)
- Table 16. Global Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Region (2026-2031) & (US$ Million)
- Table 17. Global Glucose Dependent Insulinotropic Receptor Market Share by Region (2026-2031)
- Table 18. Glucose Dependent Insulinotropic Receptor Industry Trends
- Table 19. Glucose Dependent Insulinotropic Receptor Industry Drivers
- Table 20. Glucose Dependent Insulinotropic Receptor Industry Opportunities and Challenges
- Table 21. Glucose Dependent Insulinotropic Receptor Market Restraints
- Table 22. Global Top Glucose Dependent Insulinotropic Receptor Players by Revenue (US$ Million) & (2020-2025)
- Table 23. Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Players (2020-2025)
- Table 24. Global Glucose Dependent Insulinotropic Receptor Industry Players Ranking, 2023 VS 2024 VS 2025
- Table 25. Global Key Players of Glucose Dependent Insulinotropic Receptor, Headquarters and Area Served
- Table 26. Global Glucose Dependent Insulinotropic Receptor Players, Product Type & Application
- Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Glucose Dependent Insulinotropic Receptor by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 29. Players Mergers & Acquisitions, Expansion Plans
- Table 30. North America Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 31. North America Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025) & (US$ Million)
- Table 32. North America Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031) & (US$ Million)
- Table 33. Europe Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 34. Europe Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025) & (US$ Million)
- Table 35. Europe Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031) & (US$ Million)
- Table 36. Asia Pacific Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 37. Asia Pacific Glucose Dependent Insulinotropic Receptor Market Size by Region (2020-2025) & (US$ Million)
- Table 38. Asia Pacific Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031) & (US$ Million)
- Table 39. South America Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 40. South America Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025) & (US$ Million)
- Table 41. South America Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031) & (US$ Million)
- Table 42. Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 43. Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size by Country (2020-2025) & (US$ Million)
- Table 44. Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size by Country (2026-2031) & (US$ Million)
- Table 45. Takeda Pharmaceutical Co Ltd Company Information
- Table 46. Takeda Pharmaceutical Co Ltd Business Overview
- Table 47. Takeda Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 48. Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 49. Takeda Pharmaceutical Co Ltd Recent Developments
- Table 50. Novartis AG Company Information
- Table 51. Novartis AG Business Overview
- Table 52. Novartis AG Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 53. Novartis AG Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 54. Novartis AG Recent Developments
- Table 55. Merck & Co Inc Company Information
- Table 56. Merck & Co Inc Business Overview
- Table 57. Merck & Co Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 58. Merck & Co Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 59. Merck & Co Inc Recent Developments
- Table 60. GlaxoSmithKline Plc Company Information
- Table 61. GlaxoSmithKline Plc Business Overview
- Table 62. GlaxoSmithKline Plc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 63. GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 64. GlaxoSmithKline Plc Recent Developments
- Table 65. Amgen Inc Company Information
- Table 66. Amgen Inc Business Overview
- Table 67. Amgen Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 68. Amgen Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 69. Amgen Inc Recent Developments
- Table 70. Yuhan Corp Company Information
- Table 71. Yuhan Corp Business Overview
- Table 72. Yuhan Corp Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 73. Yuhan Corp Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 74. Yuhan Corp Recent Developments
- Table 75. Taisho Pharmaceutical Holdings Co Ltd Company Information
- Table 76. Taisho Pharmaceutical Holdings Co Ltd Business Overview
- Table 77. Taisho Pharmaceutical Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 78. Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 79. Taisho Pharmaceutical Holdings Co Ltd Recent Developments
- Table 80. Kowa Co Ltd Company Information
- Table 81. Kowa Co Ltd Business Overview
- Table 82. Kowa Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 83. Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 84. Kowa Co Ltd Recent Developments
- Table 85. Hyundai Pharmaceutical Co Ltd Company Information
- Table 86. Hyundai Pharmaceutical Co Ltd Business Overview
- Table 87. Hyundai Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 88. Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 89. Hyundai Pharmaceutical Co Ltd Recent Developments
- Table 90. F. Hoffmann-La Roche Ltd Company Information
- Table 91. F. Hoffmann-La Roche Ltd Business Overview
- Table 92. F. Hoffmann-La Roche Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 93. F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 94. F. Hoffmann-La Roche Ltd Recent Developments
- Table 95. Dong-A Socio Holdings Co Ltd Company Information
- Table 96. Dong-A Socio Holdings Co Ltd Business Overview
- Table 97. Dong-A Socio Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 98. Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 99. Dong-A Socio Holdings Co Ltd Recent Developments
- Table 100. CymaBay Therapeutics Inc Company Information
- Table 101. CymaBay Therapeutics Inc Business Overview
- Table 102. CymaBay Therapeutics Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 103. CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 104. CymaBay Therapeutics Inc Recent Developments
- Table 105. Arena Pharmaceuticals Inc Company Information
- Table 106. Arena Pharmaceuticals Inc Business Overview
- Table 107. Arena Pharmaceuticals Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2020-2025) & (US$ Million)
- Table 108. Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- Table 109. Arena Pharmaceuticals Inc Recent Developments
- Table 110. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Glucose Dependent Insulinotropic Receptor Product Image
- Figure 5. Global Glucose Dependent Insulinotropic Receptor Market Size Comparison by Type (2025-2031) & (US$ Million)
- Figure 6. Global Glucose Dependent Insulinotropic Receptor Market Share by Type: 2024 VS 2031
- Figure 7. MBX-2982 Product
- Figure 8. HOB-047 Product
- Figure 9. HD-0471953 Product
- Figure 10. HD-0471042 Product
- Figure 11. GSK-2041706 Product
- Figure 12. DA-1241 Product
- Figure 13. Others Product
- Figure 14. Global Glucose Dependent Insulinotropic Receptor Market Size by Application (2025-2031) & (US$ Million)
- Figure 15. Global Glucose Dependent Insulinotropic Receptor Market Share by Application: 2024 VS 2031
- Figure 16. Type 2 Diabetes Product
- Figure 17. Obesity Product
- Figure 18. Chronic Obstructive Pulmonary Disease (COPD) Product
- Figure 19. Dyslipidemia Product
- Figure 20. Others Product
- Figure 21. Global Glucose Dependent Insulinotropic Receptor Market Size (US$ Million), Year-over-Year: 2020-2031
- Figure 22. Global Glucose Dependent Insulinotropic Receptor Market Size, (US$ Million), 2020 VS 2024 VS 2031
- Figure 23. Global Glucose Dependent Insulinotropic Receptor Market Share by Region: 2024 VS 2031
- Figure 24. Global Glucose Dependent Insulinotropic Receptor Market Share by Players in 2024
- Figure 25. Global Glucose Dependent Insulinotropic Receptor Manufacturers Established Date
- Figure 26. Global Top 5 and 10 Glucose Dependent Insulinotropic Receptor Players Market Share by Revenue in 2024
- Figure 27. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 28. North America Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 29. North America Glucose Dependent Insulinotropic Receptor Market Share by Country (2020-2031)
- Figure 30. United States Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 31. Canada Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 32. Mexico Glucose Dependent Insulinotropic Receptor Market Share by Country (2020-2031)
- Figure 33. Europe Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 34. Europe Glucose Dependent Insulinotropic Receptor Market Share by Country (2020-2031)
- Figure 35. Germany Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 36. France Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 37. U.K. Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 38. Italy Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 39. Spain Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 40. Russia Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 41. Netherlands Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 42. Nordic Countries Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 43. Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 44. Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Share by Country (2020-2031)
- Figure 45. China Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 46. Japan Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 47. South Korea Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 48. India Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 49. India Glucose Dependent Insulinotropic Receptor Market Share by Country (2020-2031)
- Figure 50. Australia Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 51. China Taiwan Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 52. Southeast Asia Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 53. South America Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 54. South America Glucose Dependent Insulinotropic Receptor Market Share by Country (2020-2031)
- Figure 55. Brazil Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 56. Argentina Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 57. Chile Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 58. Colombia Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 59. Peru Glucose Dependent Insulinotropic Receptor Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 60. Takeda Pharmaceutical Co Ltd Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 61. Novartis AG Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 62. Merck & Co Inc Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 63. GlaxoSmithKline Plc Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 64. Amgen Inc Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 65. Yuhan Corp Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 66. Taisho Pharmaceutical Holdings Co Ltd Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 67. Kowa Co Ltd Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 68. Hyundai Pharmaceutical Co Ltd Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 69. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 70. Dong-A Socio Holdings Co Ltd Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 71. CymaBay Therapeutics Inc Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
- Figure 72. Arena Pharmaceuticals Inc Revenue Growth Rate in Glucose Dependent Insulinotropic Receptor Business (2020-2025)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



